Van Es A, Tanke H J, Baldwin W M, Oljans P J, Ploem J S, Vanes L A
Clin Exp Immunol. 1983 Apr;52(1):13-20.
Peripheral blood T lymphocyte subpopulations were monitored in 45 consecutive adult recipients of cadaveric renal allografts by using monoclonal antibodies and flow cytometrie. All patients were treated with low dose corticosteroids and azathioprine. In 37 patients pre-transplant OKT4/OKT8 ratios were available. Six of 26 patients (23%) with pre-transplant OKT4/OKT8 ratios greater than 1.6 and seven of 11 patients (64%) with pre-transplant OKT4/OKT8 ratio less than or equal to 1.6 lost their graft due to rejection within 6 months. The difference in transplant survival between patients with pre-transplant OKT4/OKT8 ratios greater than 1.6 and less than or equal to 1.6i is just significant (P = 0 . 049 Fishers test). No correlation was found between post-transplant values of individual lymphocyte subpopulations or OKT4/OKT8 ratios and the incidence of subsequent rejection episodes. Forty out of 45 patients suffered one or more rejection episodes which were treated by raising the dosage of prednisone. In 24 of these patients the rejection episode was reversed, leading to a transplant survival of at least 6 months. In these 24 patients the OKT4/OKT8 ratio was greater than 1.6 for at least 3 days before the institution of any rejection treatments. Sixteen patients lost their graft due to rejection within 6 months after transplantation. In 11 of these 16 patients OKT4/OKT8 ratios less than or equal to 1.6 preceded the institution of all rejection treatments for at least 3 days, while in three patients the OKT4/OKT8 ratio was greater than 1.6 before the first rejection episode but this ratio was less than or equal to 1.6 before subsequent rejection episodes. Thus, OKT4/OKT8 ratios greater than 1.i6 correlated with reversible rejection episodes and OKT4/OKT8 ratios less than or equal to 1.6 correlated with irreversible rejection (P less than 0 . 001).
采用单克隆抗体和流式细胞术对45例连续接受尸体肾移植的成年受者外周血T淋巴细胞亚群进行监测。所有患者均接受低剂量皮质类固醇和硫唑嘌呤治疗。37例患者有移植前OKT4/OKT8比值数据。移植前OKT4/OKT8比值大于1.6的26例患者中有6例(23%),移植前OKT4/OKT8比值小于或等于1.6的11例患者中有7例(64%)在6个月内因排斥反应失去移植肾。移植前OKT4/OKT8比值大于1.6和小于或等于1.6的患者移植肾存活情况的差异具有统计学意义(P = 0.049,Fisher检验)。未发现移植后单个淋巴细胞亚群的值或OKT4/OKT8比值与随后排斥反应的发生率之间存在相关性。45例患者中有40例发生了一次或多次排斥反应,通过增加泼尼松剂量进行治疗。其中24例患者的排斥反应得到逆转,移植肾存活至少6个月。在这24例患者中,在开始任何排斥反应治疗前至少3天,OKT4/OKT8比值大于1.6。16例患者在移植后6个月内因排斥反应失去移植肾。在这16例患者中,11例在开始所有排斥反应治疗前至少3天OKT4/OKT8比值小于或等于1.6,而3例患者在首次排斥反应前OKT4/OKT8比值大于1.6,但在随后的排斥反应前该比值小于或等于1.6。因此,OKT4/OKT8比值大于1.6与可逆性排斥反应相关,OKT4/OKT8比值小于或等于1.6与不可逆性排斥反应相关(P小于0.001)。